No registrations found.
ID
Source
Brief title
Health condition
Human metapneumovirus infection
Sponsors and support
Intervention
Outcome measures
Primary outcome
Gain insight into likely shifts in incidence of HMPV, both in children and adults, between 2016 and 2021.
Secondary outcome
- Gain insight in patients admitted with HMPV between 1/6/21 and 1/8/21 as to whether it is 1 cluster of introduction or whether there are multiple genotypes circulating.
- Comparison of clinical manifestations and clinical outcomes of adult patients in June/July 2021 compared to the historical patient cohort from our earlier study.
- Comparison of clinical manifestations and outcomes between children and adults in June/July 2021.
Background summary
Background: Human metapneumovirus (HMPV) is a virus belonging to the Paramyxoviridae family and has been known since 2001. Symptoms may include wheezing, increased breath effort, and a severe cough. The virus is a known causative agent of pneumonia in both children and the elderly, immunocompromised and it can cause exacerbations in patients with COPD. Studies by our group showed that it can be associated with significant mortality and that the clinical picture in adults is very similar to COVID-19. However, there is an important difference with COVID-19: while COVID-19 shows itself as an erratic pandemic with high peaks and deep drops in incidence, HMPV continued to behave as a purely seasonal virus until 2020 with an annual high incidence in the spring and complete decline in the summer. However, in 2021, after a year of COVID-19 measures, there is evidence that HMPV incidence shifted from spring, in which it was now barely detected, to summer.
Purpose: Through this retrospective subject study, we want to gain insight into suspected shifts in incidence of HMPV, both in children and adults. We also want to gain insight into whether it is 1 cluster of introduction or whether there are multiple genotypes circulating. Finally, we want to compare clinical outcomes of adult patients in June/July 2021 with the previously collected historical cohort, as well as differences between children and adults in June/July 2021.
Methods: This retrospective cohort analysis will look at the incidence of HMPV infection in patients who were admitted to Zuyderland Medical Center between 1/1/16 and 1/8/21. Both children and adults will be included for this purpose.
The cohort of patients admitted between 1/6/21 and 1/8/21 will be studied in more detail. In these cases genotyping of HMPV will be performed and clinical outcomes of patients will be collected. Genotyping will be performed in close collaboration with the Erasmus University. The main clinical outcomes that will be observed are: mortality, ICU admission and length of hospital stay.
Study objective
It is expected to see a shift with respect to the prevalence of HMPV infection compared to previous cohorts.
Study design
T0= hospital admission T1= 30 days after hospital discharge
Inclusion criteria
Patients presented at Zuyderland Medical Center with HMPV infection, as determined by nasopharyngeal swab in which the PCR was positive for HMPV. These included both children and adults.
Exclusion criteria
Absence of nasopharyngeal swab. No informed consent.
Design
Recruitment
IPD sharing statement
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| NTR-new | NL9648 |
| Other | METC Z : METCZ20210130 |